Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2019-12-04 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
第四届董事会第二十八次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 28th meeting of the 4th Board of Directors of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.) held on December 4, 2019. It includes information about board member nominations, approval of financial management proposals, stock option cancellations, changes to employee stock ownership plans, and other board-level decisions. The document references compliance with company law and articles of association, and mentions that some matters will be submitted to the shareholders' meeting. The content is focused on board meeting decisions and management-level governance matters rather than financial results, audit opinions, or shareholder voting results. It is not a full annual or interim report, nor a call transcript or earnings release. It is not a proxy solicitation or voting results announcement. The document is a formal board meeting resolution announcement, which fits the category of Board/Management Information (MANG). The document length (4914 characters) and detailed content support this classification with high confidence.
2019-12-04 Chinese
独立董事候选人声明（张继承）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of a company, confirming compliance with various legal and regulatory requirements for serving as an independent director. It includes statements about qualifications, independence, and adherence to relevant laws and regulations. There are no financial statements, earnings data, or report summaries. The document is not an announcement of a report publication but a formal declaration related to board/management information. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 3751 characters, which is consistent with a detailed declaration rather than a full report.
2019-12-04 Chinese
独立董事候选人声明（郑健钊）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It contains statements about the candidate's qualifications, compliance with relevant laws and regulations, and independence criteria required by Chinese securities regulatory bodies and the Shenzhen Stock Exchange. The content is a formal declaration related to board/management personnel qualifications rather than a financial report, earnings release, or regulatory announcement. It does not contain financial data or results, nor is it an announcement of voting results or a proxy statement. Therefore, it fits best under the category of Board/Management Information (MANG), which covers announcements of changes or qualifications in the company's board of directors or senior management.
2019-12-04 Chinese
关于第一期员工持股计划存续期即将届满的提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the status and expiration of the company's first employee stock ownership plan (员工持股计划). It includes historical background, stock purchase details, dividend distributions, lock-up periods, and regulatory compliance information. The document is not a financial report like an annual or interim report, nor is it a call transcript or earnings release. It is not a simple announcement of a report publication but a substantive disclosure about the employee stock ownership plan's status and related arrangements. This type of document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-11-08 Chinese
关于实际控制人拟减持股份的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a planned reduction in shareholding by the company's actual controller, Mr. Hong Jiangyou. It details the shareholder's identity, shareholding percentages, the planned reduction amount, methods, reasons, timing, and compliance with relevant regulations. The document is a formal announcement regarding a director's or significant shareholder's transaction in company shares. It does not contain financial statements, earnings data, or management discussion. It is not a report or presentation but a regulatory announcement about shareholding changes by a major shareholder. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short (2401 characters), consistent with a notification rather than a full report.
2019-11-01 Chinese
2019年第三季度报告提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (518 characters) indicating that the company's full 2019 third quarter report has been approved and published on an official disclosure website. It does not contain the actual financial data or detailed report content but rather informs investors where to find the full report. This fits the pattern of a Report Publication Announcement (RPA) rather than the full Interim/Quarterly Report (IR).
2019-10-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.